Elacestrant

<!-- Name:DistributionId Value:8739365 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First,…

FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society…

EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population, and 26.8% vs.…

Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen…